Cutting Edge Imaging for Earlier Pancreatic Cancer Diagnosis: Evaluation of Positron Emission Tomography (PET) With the Fibroblast Activation Protein Inhibitor (FAPI)

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

Assessment of the relevance of a new medical imaging test, FAPI PET, which could detect progression or relapse earlier than other tests currently available. Ultimately, it could enable early forms of pancreatic cancer to be detected and used for screening. In addition to the usual examinations prescribed, FAPI PET scans will be repeated at several points in the treatment process. All study patients must first have been included in the Homing cohort (NCT 04363983, APHP promotion). Clinical characteristics, judgement criteria and results of biological or imaging examinations carried out as part of this cohort will be shared. Patient follow-up and participation in the study ends when conventional imaging (CT and MRI) shows disease progression, relapse or death.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Recent (\<1 month) diagnosis of non-metastatic PDAC (cyto/histologically proven, non-metastatic on CT-scan and MRI)

• Patient already enrolled in the HoMING prospective cohort (Sponsor: AP-HP, NCT04363983)

• Age \> 18 years old

• Affiliation to a social security scheme

• Signed informed consent

Locations
Other Locations
France
Institut Curie -site Saint-Cloud
RECRUITING
Saint-cloud
Contact Information
Primary
Marie-Emmanuelle LEGRIER
drci.promotion@curie.fr
0033156245765
Backup
Sandra NESPOULOUS
drci.promotion@curie.fr
0033147111654
Time Frame
Start Date: 2025-10-17
Estimated Completion Date: 2030-01-30
Participants
Target number of participants: 35
Treatments
Experimental: Prospective cohort involving repeated medical imaging with a new radiotracer (FAPI)
All patients of this study must have been previously enrolled in the HoMING cohort (NCT 04363983, sponsor APHP).
Related Therapeutic Areas
Sponsors
Leads: Institut Curie

This content was sourced from clinicaltrials.gov